"Designing Growth Strategies is in our DNA"
The global polymerase chain reaction (PCR) market size was USD 9.15 billion in 2023 and is projected to grow from USD 9.91 billion in 2024 to USD 19.23 billion by 2032 at a CAGR of 8.6% over the forecast period. Moreover, the U.S. polymerase chain reaction market size is projected to grow significantly, reaching an estimated value of USD 6.82 billion by 2032, driven by technological advancements and growing demand for innovative devices.
Polymerase chain reaction is one of the most important, powerful, and widely used techniques in modern biology. It is a molecular technique for in-vitro amplification and generating millions of copies of a specific region in a DNA strand. The rise in the prevalence of infectious diseases, cancer, and genetic diseases and the rise in the adoption of devices for the diagnosis of such diseases is the key factor responsible for elevating the polymerase chain reaction market growth during the forecast period. Moreover, increasing research and development activities in advanced molecular biology, forensic science, demand for personalized medicines, and genetic engineering are projected to drive the market growth during the forecasted timeframe.
With the sudden emergence of the COVID-19 pandemic globally, the need for accurate diagnosis of the disease has spurred magnificently across the world. The technique came out to be the most reliable resource for clinical diagnosis. This led to never-ending demand for products such as reagents, assays, and instruments from the corners of the world. Therefore, a rise in a number of polymerase chain reaction tests conducted, increasing COVID-19 prevalence, and numerous launches of products are anticipated to drive the market value of the global market during the forecast period.
Shift of Healthcare Providers from Real-time to Digital Technology to Fuel Market
The shift from real-time to digital diagnostic techniques of various diseases has been pivotal in the advancement of Polymerase Chain Reaction devices. Real-time technology has been widely implemented for clinical testing but a lack of standardization and relatively poor precision has hindered its usefulness. On the other hand, digital technology provides several benefits over real-time PCR. It includes high precision, direct quantification, high sensitivity, and better reproducibility. These factors have led to increased adoption of digital PCR technologies to diagnose various diseases. The launch of advanced systems for diagnosing diseases have led to shift of healthcare professionals toward digital devices. For instance, in November 2023, Stilla Technologies introduced Nio+, a new digital PCR system. It uses color combinations in seven channels for multiplexing targets. The system can process up to 48 of the company’s 16-well Ruby chips daily. This is projected to further propel the polymerase chain reaction industry during the forecast period.
Request a Free sample to learn more about this report.
Advancements in Techniques to Accelerate Market Growth
Polymerase chain reaction is an enzyme-driven process for amplifying a short region of DNA in vitro. Despite this power of amplification, limitations in its supporting hardware to hinder the technology from reaching its full potential. Technological advancements and growing demand for innovative devices have led to the need to launch new products. Thus, operating players are focusing on the research & development and introduction of innovative products to cater to changing market demands. The introduction of innovative devices by the key market players is anticipated to drive the global market during the forecast period. For instance, in November 2019, Bio-Rad Laboratories, Inc. announced the launch of QX ONE Droplet Digital PCR System, designed for drug development and manufacturing quality control, as well as other highly critical testing environments.
Growing Prevalence of Tuberculosis and Other Infectious Diseases to Fuel Demand Globally
Tuberculosis is among the most common infectious diseases, which is significantly prevalent in emerging countries. According to the World Health Organization (WHO) data published in November 2023, the number of deaths caused by tuberculosis was 1.3 million in 2022. An estimated 10.6 million individuals fell ill due to TB. China, India, and Indonesia were among the countries with a higher proportion of the population suffering from the condition. According to the World Health Organization (WHO), more than 3.7 billion people (67% of the population) globally are infected with herpes simplex virus type 1 (HSV-1). The high prevalence of such diseases requires rapid diagnosis, boosting the demand for PCR-based diagnostic tests. The higher demand for the products for diagnosis, and thus poised to accelerate the market growth.
High Cost of Assays Coupled with Lack of Awareness in Emerging Nations to Hamper Growth
Despite the increasing prevalence of infectious diseases globally certain factors that are limiting the adoption of devices for the diagnostic application. One of the major factors restraining the growth of this market is the lack of awareness about the technology market in low-income countries. In addition, high cost of assays conducted in emerging nations is likely to decrease the adoption of the devices resulting in limiting the market growth. For instance, according to the Skytrax statistics 2021 report, a test in Kansai, Japan cost around USD 404 as compared to New York, U.S. that cost around USD 179. Thus, higher cost of the assays is anticipated to lower the uptake of the test during the forecast period.
Rapid Demand for Real-time Devices to Help Proliferate Market Growth
Based on type, the global market is segmented into standard, real-time, and digital PCR.
The real-time PCR segment dominated the global market share in 2023. Increasing demand owing to the COVID-19 pandemic spurred the growth in the sales of the companies. Additionally, technological advances coupled with new product launch by the key players have been instrumental in the dominance of real-time devices in the global market. For instance, in August 2023, Gold Standard Diagnostics introduced a new product line called DNAllergen real-time PCR kits with higher sensitivity.
Digital PCR segment is projected to register a significant CAGR during the forecast period. Introduction of new product launches by market players and shifting patient preference towards products based on digital technology are factors projected to fuel the demand for this type and promote the global market growth during the forecast period.
To know how our report can help streamline your business, Speak to Analyst
Strong Sales of Reagents and Consumables Owing to Increased R&D
In terms of product, the market includes instruments and reagents & consumables.
Reagents and consumables segment dominated the market owing to their high usage in assays. Increasing prevalence of infectious diseases such as COVID-19 are contributing to the growing demand for reagents and consumables across the globe. Continuous improvements in the DNA or RNA amplification has led to greater demand for these technologies in the market. For instance, in March 2021, PCR Biosystems announced the launch of IsoFast Bst Polymerase reagents for rapid amplification of nucleic acid.
However, the instruments segment is expected to grow at a slower pace. Technologically advanced instruments and their increasing adoption are some of the factors attributable to this growth.
Clinically Proven Effectiveness of the Technology in Infectious Diseases to Aid Dominance of Segment
In terms of indication, the market is segmented into infectious diseases, oncology, genetic disorders, and others.
Among them, the infectious diseases held the leading position in the global polymerase chain reaction market. Proven effectiveness of the technology in diagnosing infectious diseases such as COVID-19, influenza among others is primarily attributable for the higher sales of products in the global market. For instance, according to Worldometer statistics, more than 236 million COVID-19 cases have been diagnosed till October 2021. Moreover, this technology has been endorsed by WHO for rapid diagnosis of pulmonary tuberculosis, replacing the standard sputum smear microscopy method. This will further propel the demand for the products during the forecast period.
Growing prevalence of cancer in countries globally owing to the changes in lifestyle patterns is contributing to the adoption of this technology by number of hospitals and diagnostic centers. In addition, launch of sophisticated technologies to provide accurate diagnosis is expected to drive the growth of the segment by 2028.
Higher Adoption of Devices by Diagnostic Centers to Enable Dominance of Segment
Based on end-users, the global market segments include hospitals & clinics, pharmaceutical & biotechnology industries, diagnostic centers, and academic & research organizations.
Among them, the diagnostic center segment held the dominating share of the market. Growing number of diagnostic centers focusing on the use of advanced methods for diagnosis of various diseases is likely to drive the segment growth. Moreover, adequate reimbursement policies provided by these centers are the major factors responsible for increasing the popularity of diagnostic centers.
The segment is projected to continue its dominance by expanding at a significantly high growth rate during the forecast period. Growing use of this technology in drug development and other research activities will augment the growth of the products in pharmaceutical and biotechnology industries.
North America Polymerase Chain Reaction (PCR) Market Size, 2023 (USD Billion)
To get more information on the regional analysis of this market, Request a Free sample
North America to Hold Largest Market Share due to Rising Awareness Among Patient Pool
The global polymerase chain reaction market size in North America was valued at USD 3.66 billion in 2023. The leading position is attributable to the growing prevalence of infectious diseases coupled with adequate reimbursement policies for the devices. In addition, increasing awareness among the patient population about availability of advanced products for effective diagnosis is another factor responsible for the region enjoying the dominant market share.
Europe is the second largest region due to rising incidence of chronic diseases demanding precise diagnosis. For instance, according to GLOBOCAN 2020, Europe reported around 4,398,443 new cancer cases. In addition, growing merger and acquisitions in the region is majorly contributing to the market value during the forecast period.
The market in Asia Pacific is estimated to register a higher CAGR during the forecast period. Increased adoption rate of the devices coupled with presence of a large and underpenetrated market are projected to drive the Asia Pacific market growth during the forecast period. Moreover, rapid launch of products in the region owing to the growing demand for advanced assays is likely to facilitate the higher revenue growth in the region. For example, in June 2020, Singapore based Lucence Diagnostics announced the launch of SARS-CoV-2 RNA RT-PCR test indicated for diagnosis of COVID-19 infections.
The market in Latin America and the Middle East & Africa are expected to witness a substantial growth owing to the lesser adoption rate and launch of products. However, the efforts in developing healthcare infrastructure is expected to boost the product demand during the forecast period.
Diverse Portfolio of Leading Players and Strong Focus on Partnerships and Acquisition to Strengthen Their Market Position
The competitive landscape of the global polymerase chain reaction industry’s growth indicates the emergence of Bio-Rad Laboratories, Inc., QIAGEN, F. Hoffmann-La Roche Ltd, and Agilent Technologies, Inc. as the leading players. A diversified product portfolio of real-time and digital PCR, along with constant innovations by the companies leading to new product launches, are prominent factors responsible for the dominance of the companies. For instance, in April 2021, Bio-Rad Laboratories Inc. announced the launch of Reliance SARS-CoV-2 RT-PCR Assay in Europe for clinical diagnosis of coronavirus. Moreover, a strong emphasis on partnerships and acquisition strategies in the market is likely to help attract high revenue in the forthcoming years.
The market research report provides a detailed analysis of the market and focuses on key aspects such as leading companies, product types, and leading applications of the product. Besides this, the report offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over recent years.
To gain extensive insights into the market, Request for Customization
ATTRIBUTE | DETAILS |
Study Period | 2019-2032 |
Base Year | 2023 |
Estimated Year | 2024 |
Forecast Period | 2024-2032 |
Historical Period | 2019-2022 |
Growth Rate | CAGR of 8.6% from 2024-2032 |
Unit | Value (USD billion) |
Segmentation | By Type
|
By Product
| |
By Indication
| |
By End User
| |
By Geography
|
Fortune Business Insights says the global market will be worth USD 19.23 billion by 2032.
In 2023, the market value stood at USD 9.15 billion.
Growing at a CAGR of 8.6%, the market will exhibit steady growth over the forecast period (2024-2032).
Real-time PCR segment is the leading segment in this market during the forecast period.
Growing prevalence of tuberculosis and other infectious diseases, increasing new product launches, and growing penetration of players in untapped markets are key factors driving the market.
Bio-Rad Laboratories, Inc., QIAGEN, F. Hoffmann-La Roche Ltd, and Agilent Technologies, Inc. are the top players in the market.
North America dominated the market share in 2023.
Shift of healthcare providers from real-time to digital PCR is the major trend in the market.
US +1 833 909 2966 ( Toll Free )